Demo
APLT Nasdaq· Applied Therapeutics Inc.
FundamentalsNews digest Peer analysis
Login
APLT Nasdaq· Applied Therapeutics Inc.
Earnings report Q3 2023

Applied Therapeutics Reports No License Revenue in Latest Quarter

Segments of revenue

Applied Therapeutics reported no license revenue in the latest quarter. The total revenue for the quarter was $10.66 million.

Strengths

Despite the lack of license revenue, Applied Therapeutics managed to generate $10.66 million in total revenue for the quarter. This indicates that the company has other sources of revenue apart from licensing. Management comments were not provided in the report.

Challenges

The lack of license revenue in the latest quarter is a weakness for Applied Therapeutics. License revenue is an important source of income for the company, and its absence could impact the overall financial performance. The company needs to focus on securing licensing deals to boost its revenue.

Noteworthy

It is worth noting that Applied Therapeutics did not provide any explanation for the absence of license revenue in the latest quarter. This could be due to various factors such as the expiration of existing licenses or the delay in signing new licensing agreements. However, without further information, it is difficult to determine the exact reason.

Summary

Applied Therapeutics reported no license revenue in the latest quarter, resulting in a total revenue of $10.66 million. While the company managed to generate revenue from other sources, the absence of license revenue is a weakness that needs to be addressed. The company should focus on securing new licensing deals to improve its financial performance.

Source documents

Form 10-Q  filed on Nov 09, 2023
19 pages scanned

Reference data

Company financials Q3 revenue -667k
Analyst estimates Q3 EPS beat by 35.08%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.